DE69723982D1 - Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndroms - Google Patents
Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromsInfo
- Publication number
- DE69723982D1 DE69723982D1 DE69723982T DE69723982T DE69723982D1 DE 69723982 D1 DE69723982 D1 DE 69723982D1 DE 69723982 T DE69723982 T DE 69723982T DE 69723982 T DE69723982 T DE 69723982T DE 69723982 D1 DE69723982 D1 DE 69723982D1
- Authority
- DE
- Germany
- Prior art keywords
- growth hormone
- patient
- igf
- serum level
- below normal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 5
- 108010051696 Growth Hormone Proteins 0.000 title abstract 5
- 239000000122 growth hormone Substances 0.000 title abstract 5
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 230000035945 sensitivity Effects 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 3
- 210000002966 serum Anatomy 0.000 abstract 3
- 102100020948 Growth hormone receptor Human genes 0.000 abstract 1
- 208000006302 Laron syndrome Diseases 0.000 abstract 1
- 208000022967 Short stature due to partial GHR deficiency Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 108010033419 somatotropin-binding protein Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US643212 | 1991-01-24 | ||
| US08/643,212 US6207640B1 (en) | 1994-04-07 | 1996-05-03 | Treatment of partial growth hormone insensitivity syndrome |
| PCT/US1997/006652 WO1997041887A1 (en) | 1996-05-03 | 1997-04-18 | Treatment of partial growth hormone insensitivity syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69723982D1 true DE69723982D1 (de) | 2003-09-11 |
| DE69723982T2 DE69723982T2 (de) | 2004-07-22 |
Family
ID=24579841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69723982T Expired - Lifetime DE69723982T2 (de) | 1996-05-03 | 1997-04-18 | Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndroms |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6207640B1 (de) |
| EP (2) | EP1369125A1 (de) |
| JP (1) | JP2001510444A (de) |
| AT (1) | ATE246511T1 (de) |
| CA (1) | CA2252560C (de) |
| DE (1) | DE69723982T2 (de) |
| DK (1) | DK0914148T3 (de) |
| ES (1) | ES2205211T3 (de) |
| PT (1) | PT914148E (de) |
| WO (1) | WO1997041887A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| WO1999003887A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| EP2305804B1 (de) * | 1999-01-14 | 2015-05-06 | Bolder Biotechnology, Inc. | MonoPEGyliertes menschliches Wachstumshormon |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| ATE361761T1 (de) * | 2002-09-27 | 2007-06-15 | Hoffmann La Roche | Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4 |
| ES2541673T3 (es) * | 2003-09-12 | 2015-07-23 | Ipsen Biopharmaceuticals, Inc. | Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (IGF-1) |
| UA108994C2 (uk) * | 2009-11-17 | 2015-07-10 | Ипсен Фарма С.А.С. | Фармацевтична композиція, що містить комбінацію hgh і rhigf-1, і процес її приготування (варіанти) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
| US5824642A (en) * | 1994-04-07 | 1998-10-20 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US5646113A (en) * | 1994-04-07 | 1997-07-08 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
-
1996
- 1996-05-03 US US08/643,212 patent/US6207640B1/en not_active Expired - Lifetime
-
1997
- 1997-04-18 EP EP03011410A patent/EP1369125A1/de not_active Ceased
- 1997-04-18 EP EP97921307A patent/EP0914148B1/de not_active Expired - Lifetime
- 1997-04-18 DE DE69723982T patent/DE69723982T2/de not_active Expired - Lifetime
- 1997-04-18 ES ES97921307T patent/ES2205211T3/es not_active Expired - Lifetime
- 1997-04-18 DK DK97921307T patent/DK0914148T3/da active
- 1997-04-18 WO PCT/US1997/006652 patent/WO1997041887A1/en active IP Right Grant
- 1997-04-18 AT AT97921307T patent/ATE246511T1/de active
- 1997-04-18 PT PT97921307T patent/PT914148E/pt unknown
- 1997-04-18 CA CA2252560A patent/CA2252560C/en not_active Expired - Lifetime
- 1997-04-18 JP JP53993897A patent/JP2001510444A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK0914148T3 (da) | 2003-11-24 |
| DE69723982T2 (de) | 2004-07-22 |
| ES2205211T3 (es) | 2004-05-01 |
| PT914148E (pt) | 2003-12-31 |
| EP0914148A1 (de) | 1999-05-12 |
| EP0914148B1 (de) | 2003-08-06 |
| CA2252560C (en) | 2010-12-14 |
| ATE246511T1 (de) | 2003-08-15 |
| US6207640B1 (en) | 2001-03-27 |
| CA2252560A1 (en) | 1997-11-13 |
| JP2001510444A (ja) | 2001-07-31 |
| WO1997041887A1 (en) | 1997-11-13 |
| EP1369125A1 (de) | 2003-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69521796D1 (de) | Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes | |
| TW264480B (de) | ||
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| SE8703625D0 (sv) | New medical use | |
| DE69031168D1 (de) | Verwendung von IGF1 oder IGF2 zur Herstellung eines Medikaments für die Behandlung von amyotrophischen Lateralsklerose | |
| EP0526544A4 (en) | Therapeutic uses of actin-binding compounds | |
| DE69616376T2 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| DE69723982D1 (de) | Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndroms | |
| DE69635305D1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
| NO975360D0 (no) | Peptid som inhiberer forhöyede triglyceridnivåer i blod og midler som inneholder nevnte peptid som aktiv komponent | |
| DE69129267D1 (de) | Methode zur behandlung intestinaler krankheiten | |
| DE69739737D1 (de) | Methode zur Behandlung von Muskelkrankheiten | |
| ATE183651T1 (de) | Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen | |
| ES2087337T3 (es) | Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos. | |
| DE69113773D1 (de) | Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma. | |
| ATE251640T1 (de) | Neues chondrozytprotein | |
| MX9206339A (es) | Nueva proteina inhibidora de trombina a partir de chinches de monte | |
| BR9006746A (pt) | Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio | |
| Eijking | Surfactant inhibition in acute respiratory failure: consequences for exogenous surfactant therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |